Bioalliance PharmaAct Nom. Cat-P News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.05.16	Onxeo S.A.: Publication of 2015 Reference Document (Businesswire)
02.05.16	Onxeo First Quarter 2016 Financial information and Business Update (Businesswire)
28.04.16	Onxeo First Quarter 2016 Financial information and Business Update (Businesswire)
18.04.16	Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment (Businesswire)
06.04.16	Passing on Onxeo’s Extraordinary and Ordinary General Meeting (Businesswire)
04.04.16	Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC (Businesswire)
25.03.16	Onxeo Announces Closing of DNA Therapeutics Acquisition (Businesswire)
21.03.16	Onxeo Announces Establishment of U.S. Subsidiary (Businesswire)
16.03.16	Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting (Businesswire)
16.03.16	Onxeo: Ordinary and Extraordinary General Meeting on April 6, 2016 (Businesswire)
29.02.16	Onxeo Announces Acquisition of DNA Therapeutics and Provides Update on Validive® Development Plan (Businesswire)
26.02.16	Onxeo Reports 2015 Full-Year Results and Provides Business Update (Businesswire)
22.02.16	Onxeo Expands Collaborations to Advance Development Program of Key Orphan Oncology Assets in Combination with Immuno-Oncology Agents (Businesswire)
17.02.16	Onxeo to Attend Upcoming Investor Conferences and Medical Meetings (Businesswire)
25.01.16	Onxeo Announces the Evolution and Reinforcement of Its Board of Directors (Businesswire)
07.01.16	ONXEO: Half-Year Report on the Liquidity Contract with CM-CIC Securities (Businesswire)
17.12.15	Onxeo S.A.: Publication of Shareholders Letter (Businesswire)
15.12.15	Onxeo announces its financial calendar for 2016 (Businesswire)
06.12.15	Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat (Beleodaq®) and Standard CHOP (Businesswire)
18.11.15	Onxeo Initiates Comprehensive Strategy to Extend Value of Key Orphan Oncology Assets (Businesswire)
18.11.15	Onxeo Initiates Comprehensive Strategy to Extend Value of Key Orphan Oncology Assets (Businesswire)
09.11.15	Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma (PTCL) (Businesswire)
05.11.15	Onxeo Reports Third Quarter 2015 Business Update (Businesswire)
28.10.15	Onxeo to attend upcoming investor events (Businesswire)
22.10.15	Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive® for Treatment of Severe Oral Mucositis (Businesswire)
19.10.15	Onxeo Validive® Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 (Businesswire)
06.10.15	Onxeo Announces Evolution in the Board of Directors (Businesswire)
05.10.15	Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC (Businesswire)
30.09.15	Onxeo S.A.: Publication of a New Letter to Shareholders (Businesswire)
22.09.15	Onxeo S.A.: Decision in the litigation against Eurofins and ABL companies (Businesswire)
17.09.15	Corporate Governance prize awarded by AGEFI: Onxeo receives "Silver Governance” for the second consecutive year (Businesswire)
15.09.15	Onxeo Files Application for Key Livatag® Patent (Businesswire)
08.09.15	Onxeo to present at InvestorDagen 2015 (Businesswire)
03.09.15	Onxeo S.A.: Publication of a Shareholders Letter (Businesswire)
03.09.15	Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at August 31, 2015 (Businesswire)
31.08.15	Capital Increase in Onxeo Resulting from the Exercise of Share Subscription Options from Employees (Businesswire)
05.08.15	Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at July 31, 2015 (Businesswire)
30.07.15	Onxeo Reports First Half 2015 Business Update and Consolidated Accounts (Businesswire)
30.07.15	Onxeo Reports First Half 2015 Business Update and Consolidated Accounts (Businesswire)
21.07.15	Onxeo: Update on ReLive, Livatag® International Phase III Clinical Trial in HCC (Businesswire)
08.07.15	Onxeo : Meetings with the Financial Community During the 2nd Semester of 2015 (Businesswire)
07.07.15	Onxeo: Disclosure of total number of voting rights and number of shares in the capital at June 30, 2015 (Businesswire)
30.06.15	Onxeo: Validive® at the MASCC/ISOO International Symposium: Oral Presentation of Phase II Trial Results and Meeting with Its International Advisory Board (Businesswire)
23.06.15	Onxeo : Beleodaq® (belinostat) Pivotal BELIEF Study Results Published in the Journal of Clinical Oncology (JCO) (Businesswire)
18.06.15	Onxeo Consolidates Its Industrial Property with a US Patent Protecting Validive® until 2029 (Businesswire)
04.06.15	Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at May 31, 2015 (Businesswire)
03.06.15	Onxeo Meets US Investors During "French Life Sciences Days” Event in New York on June 17 & 18, 2015 (Businesswire)
28.05.15	Onxeo Announces Preclinical & Clinical Data from Three Studies Supporting the Potential For Belinostat in Multiple Orphan Oncology Indications (Businesswire)
26.05.15	Onxeo Announces Final Data from Completed Phase II Trial of Validive® for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients (Businesswire)
20.05.15	Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2015 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’299.00	2.40 %	K V
Holcim	89.04	1.09 %	K V
Roche Hldg G	266.90	0.95 %	K V
ABB	49.88	0.81 %	K V
Novartis	90.96	0.63 %	K V
Givaudan	3’882.00	-0.54 %	K V
Zurich Insur Gr	547.20	-0.83 %	K V
Alcon	76.34	-1.14 %	K V
Logitech Intl	78.74	-1.43 %	K V
Geberit	505.80	-1.52 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bioalliance PharmaAct Nom. Cat-P

Aktien Top/Flop

Meistgelesene Nachrichten